Home > Press > BioForce Nanosciences Exceeds 2006 Goal for Shipping Nano eNabler(TM) Printers
Abstract:
BioForce Nanosciences,Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH.OB), announced that it exceeded its 2006 goal for
shipping up to 20 of its cutting-edge Nano eNabler(TM) molecular printers
to prestigious institutions across the globe. BioForce exceeded its goal by
two units by year end. These pilot placements of the Company's patented
Nano eNabler device at centers of research excellence, allow the
entrepreneurial researchers at those centers to act as "early adopters" of
BioForce's practical tools and technologies.
"With the shipment of these 22 Nano eNabler molecular printers," says
BioForce Product Manager Michael Lynch, "BioForce is now essentially
partnering with an impressive group of innovators working in the micro and
nanotechnology fields. Several groups have already expressed a desire to
seek funds to convert their placement into a purchase."
Kerry Frey, BioForce's chief operating officer, says, "BioForce
Nanosciences is positioned between two very exciting markets-nanotechnology
and the life sciences. We strongly believe our Nano eNabler system will
change how research is conducted in laboratories across the world." He
explains that the ease of use and practicality provided by the Nano eNabler
system, establish a path from laboratory to industry.
Institutions where recent placements have taken place:
* University of California, Cal-it2, Irvine, CA
* Cornell University, NanoBioTechnology Center, Ithaca, NY
* ETH Zurich, Zurich, Switzerland
* Georgia Institute of Technology, Microelectronics Research Center,
Atlanta, GA
* Stanford University, James H. Clark Center, Stanford, CA
####
About BioForce Nanosciences
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). BioForce
Nanosciences is a unique company entering into commercialization with over
a decade of research and accomplishment in the field of bionanotechnology.
BioForce has demonstrated the ability to take a product from concept to
commercial sale. For more information, visit http://www.bioforcenano.com.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
Contacts:
Phone: 515.233.8333
Fax: 515.233.8337
E-mail:
Copyright © PR Newswire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||